Pantarhei Bioscience B.v.

Donesta Bioscience B.v.

Akzo Nobel N.v.

Estetra S.p.r.l.

Oxytone Bioscience B.v.

Ares Trading S.a.

Akzo Nobel

Herman Jan Tijmen Coelingh Bennink

Evert Johannes Bunschoten

Christian Franz Holinka

Johannes Jan Platteeuw

Monique Visser

Jean-Michel Foidart

Michiel Christian Alexander Van Vliet

Nafis Ahmed Rahman

Martinus Antonius Hermanus Maria Wiegerinck

Petrus Johannes Boerrigter

René Frank Van Der Linden

Wout Wouters

Bernadette Maria Julia Louise Mannaerts

Everardus Otto Maria Orlemans

Franciscus Wilhelmus Petrus Damen

Ludivine Petit

Pieter M Verbost

Carole Verhoeven

The present invention relates to treatment and diagnosis of lung cancer and metastases thereof. More specifically, the invention relates to such therapeutic use of antigen sources providing immunogenic polypeptides comprising at least an immunogenic portion of a cancer cell associated protein, which preferably is a zona pellucida (ZP) protein, especially a ZP3 protein or the extracellular domain thereof, whereby the antigen source induces a cellular immune response against the lung cancer cells. The antigen source can be a proteinaceous composition comprising such immunogenic ZP polypeptide, a nucleic acid encoding the immunogenic ZP polypeptide, or a cell expressing or presenting the immunogenic ZP polypeptide. In addition, the invention relates to the therapeutic use of a T cell comprising a T cell receptor that binds an MHC-peptide complex, wherein the peptide is a peptide from the immunogenic ZP polypeptide. The invention further relates to the therapeutic and/or diagnostic use of antibodies that specifically binds to the immunogenic ZP polypeptide.

Immunotherapeutic method for treating lung cancer by administering a polypeptide comprising an epitope of hZP3

The present invention relates to a process for the preparation of estra-1,3,5(10)-trien-3, 15a, 16a, 17&#x3b2;-tetraol (estetr-01), via a silyl enol ether derivative 17-B-oxy-3-A-oxy-estra-1,3,5(10), 16-tetraene, wherein A is a protecting group and B is &#x2014;Si(R). The invention further relates to a process for the synthesis of 3-A-oxy-estra-1,3,5(10), 15-tetraen-17-one, in which A is a protecting group, via silyl enol ether derivative 17-B-oxy-3-A-oxy-estra-1,3,5(10),16-tetraene, and B is &#x2014;Si(R).

Process for the preparation of estetrol

The present invention provides an orally disintegrating solid pharmaceutical dosage unit having a weight between 50 and 1,000 mg, said dosage unit consisting of: 1-100 wt. % of particles consisting of: 0.01-10 wt. % of a partus control substance selected from oxytocin, carbetocin, atosiban and combinations thereof; 5-70 wt. % of buffering agent; 20-94 wt. % of branched glucan; 0-70 wt. % of other pharmaceutically acceptable ingredients; 0-95 wt. % of one or more pharmaceutically acceptable excipients; the solid dosage unit comprising at least 5 &#x3bc;g of the partus control substance and having a pH buffer range of 3.5-5.7. The solid dosage unit of the present invention is easy to manufacture and perfectly suited for sublingual, buccal or sublabial administration. Furthermore, the dosage unit does not need to be stored and distributed under temperature controlled conditions.

Orally disintegrating solid pharmaceutical dosage unit containing a partus control substance

The present invention relates to a method of treating or preventing estrogen-sensitive tumours in a mammal, said method comprising the administration of a therapeutically effective amount of an estrogenic component to said mammal, wherein the estrogenic component is selected from the group consisting of: substances represented by the following formula in which formula R, R, R, Rindependently are a hydrogen atom, a hydroxyl group or an alkoxy group with 1-5 carbon atoms; precursors capable of liberating a substance according to the aforementioned formula when used in the present method; and mixtures of one or more of the aforementioned substances and/or precursors. The estrogenic component according to the invention does not have undesirable proliferative effects on breast and/or endometrial tissue and displays sufficient estrogenicity to prevent that its administration will lead to hypoestrogenism and/or climacteric complaints. Other aspects of the invention relate to pharmaceutical compositions, drug delivery systems and kits comprising the aforementioned estrogenic component in combination with an estrogen suppressant.

Pharmaceutical composition comprising estetrol derivatives for use in cancer therapy

The present invention relates to a tablet having a weight of 30-200 mg and consisting of: These tablets can suitably be used to orally administer DHEA in dosages of around 50 mg and are sufficiently small to be incorporated in, for instance, ordinary oral contraceptive blister packs.

Tablet containing dehydroepiandrosterone (DHEA)

An orally disintegrating solid pharmaceutical dosage unit having a weight between 50 and 1,000 mg is disclosed. The dosage unit consists of: (a) 5-100 wt. % of coated particles comprising 50-99 wt. % of a core particle and 1-50 wt. % of a coating that envelops the core particle, said coating consisting of:

The present invention provides an orally disintegrating solid pharmaceutical dosage unit having a weight of 50-1,000 mg and containing at least 0.1 mg of an estetrol component selected from estetrol, estetrol esters and combinations thereof. This solid dosage unit consists of: The solid dosage units of the present invention are particularly suited for sublingual, buccal or sublabial administration of the estetrol component.

Orally disintegrating solid dosage unit containing an estetrol component

The present invention provides an orally disintegrating solid pharmaceutical dosage unit having a weight of 50-1,000 mg and containing at least 0.1 mg of an estetrol component selected from estetrol, estetrol esters and combinations thereof. This solid dosage unit consists of: 4-95 wt. % of granules consisting of: 3-80 wt. % of an estetrol component selected from estetrol, estetrol esters and combinations thereof; 20-97 wt. % C-Csugar alcohol; 0-45 wt. % of one or more other pharmaceutically acceptable ingredients; and 5-96 wt. % of one or more pharmaceutically acceptable excipients. The solid dosage units of the present invention are particularly suited for sublingual, buccal or sublabial administration of the estetrol component.

The present invention relates to a new use of tetrahydroxylated estrogens such as estetrol (1,3,5(10)-estratrien-3, 15&#x3b1;, 16&#x3b1;, 17&#x3b2;-tetrol), namely in a method of emergency contraception. The method of emergency contraception according to the invention comprises the oral administration of estetrol in a single dose within 120 hours of sexual intercourse.

Use of estetrol as emergency contraceptive

The present invention relates to a method of treating or preventing estrogen-suppressed tumors in a mammal, said method comprising the administration of a therapeutically effective amount of an estrogenic component to said mammal, wherein the estrogenic component is selected from the group consisting of: substances represented by the following formula in which formula R, R, R, Rindependently are a hydrogen atom, a hydroxyl group or an alkoxy group with 1-5 carbon atoms; precursors capable of liberating a substance according to the aforementioned formula when used in the present method; and mixtures of one or more of the aforementioned substances and/or precursors. The estrogenic component according to the invention is particularly useful in the treatment or prevention of colorectal and prostate cancer and, unlike commonly used estrogens, does not simultaneously enhance the risk of estrogen-stimulated cancers such as breast cancer.

Pharmaceutical compositions comprising estetrol derivatives for use in cancer therapy

The invention relates to treatment of prostate cancer and metastases thereof. More specifically, the invention relates to immunogenic polypeptides comprising at least a portion of a prostatic tumor cell-associated protein or immunologically active variants thereof and to nucleic acids encoding such polypeptides and to the use thereof in immunotherapeutic methods of treatment of prostate cancer. Said immunogenic polypeptides are provided by the zona pellucida (ZP) (glyco)proteins. ZP (glyco)proteins and fragments thereof that can induce a CD8and/or CD4T cell response as well as nucleic acid sequences encoding them can suitably be used in the present immunotherapeutic strategies.

Immunotherapeutic method for treating prostate cancer

One aspect of the invention concerns a cosmetic method of treating human skin by delivering an estrogenic component to said skin. The method comprises applying to the skin a composition containing: (i) at least 5 &#x3bc;g/g of an estrogenic component selected from the group consisting of substances represented by the following formula (I) in which formula R, R, R, Rindependently are a hydrogen atom, a hydroxyl group or an alkoxy group with 1-5 carbon atoms; each of R, R, Ris a hydroxyl group; no more than 3 of R, R, R, Rare hydrogen atoms; precursors capable of liberating a substance according to the aforementioned formula when used in the present method; and mixtures of one or more of the aforementioned substances and/or precursors; and (ii) a cosmetically acceptable vehicle. Other aspects of the invention relate to therapeutic methods of treating or preventing vaginal dryness or acne and a therapeutic method of promoting wound healing. Yet another aspect of the invention relates to a skin care composition comprising the aforementioned estrogenic component and a cosmetically acceptable vehicle.

Method of treating human skin and a skin care composition for use in such a method

The present invention relates to a method of treating or preventing estrogen-sensitive tumors in a mammal, said method comprising the administration of a therapeutically effective amount of an estrogenic component to said mammal, wherein the estrogenic component is selected from the group consisting of: substances represented by the following formula in which formula R, R, R, Rindependently are a hydrogen atom, a hydroxyl group or an alkoxy group with 1-5 carbon atoms; precursors capable of liberating a substance according to the aforementioned formula when used in the present method; and mixtures of one or more of the aforementioned substances and/or precursors. The estrogenic component according to the invention does not have undesirable proliferative effects on breast and/or endometrial tissue and displays sufficient estrogenicity to prevent that its administration will lead to hypoestrogenism and/or climacteric complaints.

The present invention relates to a method of treating or preventing estrogen-suppressed tumors in a mammal, said method comprising the administration of a therapeutically effective amount of an estrogenic component to said mammal, wherein the estrogenic component is selected from the group consisting of: substances represented by the following formula (I) in which formula R, R, R, R, independently are a hydrogen atom, a hydroxyl group or an alkoxy group with 1-5 carbon atoms; precursors capable of liberating a substance according to the aforementioned formula when used in the present method; and mixtures of one or more of the aforementioned substances and/or precursors. The estrogenic component according to the invention is particularly useful in the treatment or prevention of colorectal and prostate cancer and, unlike commonly used estrogens, does not simultaneously enhance the risk of estrogen-stimulated cancers such as breast cancer.

Sampler for self-sampling of samples from a body cavity, such as cervical samples. Optimum accessibility of the cervix is achieved through the sampler comprising a rigid plastic tube which is rounded at the front side. During its introduction, the sampler can accurately be moved to the cervix. The sampler is surrounded by the vagina and can prevent leakage of flushing liquid, and it is possible to use a relatively small quantity of flushing liquid while producing a sample with a high concentration of cervical cells. It is possible to reach the sampling location in a simple and more accurate way which does not damage tissue. As a result of the tube simultaneously being designed as a cylinder for a plunger, it is possible, to flush the desired location with a solution using a cylinder-plunger and, to take the sample by drawing the plunger back.

Growing community of inventors

Driebergen, Netherlands

Herman Jan Tijmen Coelingh Bennink